AND EXCHANGE COMMISSION
to Section 13 or 15(d) of the Securities Exchange Act of 1934
of Report (Date of earliest event reported): July 10, 2020
name of registrant as specified in its charter)
or Other Jurisdiction
McKinney Avenue, 7th Floor
of Principal Executive Offices)
telephone number, including area code)
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
registered pursuant to Section 12(b) of the Act: Common Stock
|Title of each class||
||Name of each exchange on which registered|
|Common Stock, $0.0001 par value||
||The Nasdaq Stock Market|
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
growth company þ
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
1.01 Entry into a Material Definitive Agreement.
July 10, 2020, we entered into an agreement with Patheon API Services, Inc. (“Patheon”) for the manufacture and supply
of cGMP material to support our planned Phase II clinical trial for our product candidate LP-300.
addition to producing LP-300 API (active pharmaceutical ingredient) under cGMP (current Good Manufacturing Practices) conditions,
Patheon will transfer previously validated manufacturing processes and analytical methods for LP-300 and will produce non-GMP
material that can be used to support non-clinical studies for LP-300. The agreement provides for payments in stages as specified
process and manufacturing milestones are achieved.
a part of Thermo Fisher Scientific, has previously developed and/or manufactured more than 700 pharmaceuticals for biopharma clients
and has more than 55 locations around the world, providing access to a fully integrated global network of facilities.
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
July 16, 2020
David R. Margrave|
R. Margrave, Chief Financial Officer|